| Cardiovascular Health and Risk Factors | Lifetime | 32 | CN 1 | 99.38 |
| Glycosylation and Glycoproteins Research | Lifetime | 199 | CN 4 | 99.14 |
| Monoclonal and Polyclonal Antibodies Research | Lifetime | 441 | CN 4 | 99.20 |
| Epigenetics and DNA Methylation | Lifetime | 441 | CN 27 | 98.86 |
| Galectins and Cancer Biology | Lifetime | 128 | CN 1 | 98.31 |
| Cancer-related molecular mechanisms research | Lifetime | 885 | CN 403 | 97.66 |
| Tuberculosis Research and Epidemiology | Lifetime | 841 | CN 24 | 97.32 |
| Cardiac Health and Mental Health | Lifetime | 408 | CN 6 | 97.24 |
| Cancer-related Molecular Pathways | Lifetime | 892 | CN 43 | 97.16 |
| Cancer-related gene regulation | Lifetime | 789 | CN 98 | 96.47 |
| Health, psychology, and well-being | Lifetime | 269 | CN 4 | 96.52 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 824 | CN 25 | 97.40 |
| Health, Environment, Cognitive Aging | Lifetime | 310 | CN 2 | 95.62 |
| Protease and Inhibitor Mechanisms | Lifetime | 705 | CN 13 | 96.13 |
| Kawasaki Disease and Coronary Complications | Lifetime | 234 | CN 5 | 95.08 |
| Traditional Chinese Medicine Studies | Lifetime | 486 | CN 296 | 91.35 |
| Cholesterol and Lipid Metabolism | Lifetime | 800 | CN 20 | 93.76 |
| Global Healthcare and Medical Tourism | Lifetime | 103 | CN 7 | 90.92 |
| Lipid metabolism and disorders | Lifetime | 963 | CN 48 | 91.45 |
| Data-Driven Disease Surveillance | Lifetime | 591 | CN 47 | 89.53 |
| Forensic and Genetic Research | Lifetime | 998 | CN 59 | 89.07 |
| Travel-related health issues | Lifetime | 533 | CN 11 | 85.78 |
| Glycogen Storage Diseases and Myoclonus | Lifetime | 994 | CN 9 | 86.93 |
| Clinical Laboratory Practices and Quality Control | Lifetime | 755 | CN 12 | 82.22 |
| Race, Genetics, and Society | Lifetime | 764 | CN 22 | 62.78 |
| Reliability and Agreement in Measurement | Lifetime | 911 | CN 23 | 51.93 |
| Glycosylation and Glycoproteins Research | 2021-2025 | 2 | CN 1 | 99.61 |
| Galectins and Cancer Biology | 2021-2025 | 2 | CN 1 | 99.06 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 24 | CN 3 | 98.02 |
| Cardiovascular Disease and Adiposity | 2021-2025 | 83 | CN 10 | 95.82 |
| Monoclonal and Polyclonal Antibodies Research | 2021-2025 | 166 | CN 11 | 96.68 |
| Liver Disease Diagnosis and Treatment | 2021-2025 | 529 | CN 56 | 97.62 |
| Sepsis Diagnosis and Treatment | 2021-2025 | 185 | CN 13 | 96.85 |
| Epigenetics and DNA Methylation | 2021-2025 | 433 | CN 168 | 93.88 |
| Global Healthcare and Medical Tourism | 2021-2025 | 8 | CN 3 | 93.87 |
| Metabolism, Diabetes, and Cancer | 2021-2025 | 149 | CN 15 | 94.86 |
| Travel-related health issues | 2021-2025 | 18 | CN 2 | 94.44 |
| Immune Cell Function and Interaction | 2021-2025 | 654 | CN 149 | 93.22 |
| Influenza Virus Research Studies | 2021-2025 | 202 | CN 30 | 95.17 |
| T-cell and B-cell Immunology | 2021-2025 | 286 | CN 30 | 92.64 |
| Respiratory viral infections research | 2021-2025 | 383 | CN 25 | 94.01 |
| Cancer, Hypoxia, and Metabolism | 2021-2025 | 437 | CN 188 | 91.25 |
| CRISPR and Genetic Engineering | 2021-2025 | 474 | CN 193 | 92.65 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 394 | CN 40 | 94.62 |
| Infectious Diseases and Tuberculosis | 2021-2025 | 130 | CN 7 | 91.12 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 332 | CN 70 | 92.87 |
| Tuberculosis Research and Epidemiology | 2021-2025 | 469 | CN 45 | 93.85 |
| Genetic Associations and Epidemiology | 2021-2025 | 458 | CN 46 | 91.81 |
| Diabetes and associated disorders | 2021-2025 | 399 | CN 14 | 92.15 |
| Global Public Health Policies and Epidemiology | 2021-2025 | 271 | CN 9 | 88.38 |
| Mycobacterium research and diagnosis | 2021-2025 | 392 | CN 55 | 90.13 |
| Pharmacological Effects of Natural Compounds | 2021-2025 | 347 | CN 212 | 88.06 |
| Nutritional Studies and Diet | 2021-2025 | 848 | CN 95 | 91.66 |
| Virus-based gene therapy research | 2021-2025 | 660 | CN 182 | 88.26 |
| Tryptophan and brain disorders | 2021-2025 | 777 | CN 232 | 88.61 |
| Diet, Metabolism, and Disease | 2021-2025 | 489 | CN 77 | 88.48 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 512 | CN 76 | 87.54 |
| Health, Environment, Cognitive Aging | 2021-2025 | 395 | CN 32 | 87.21 |
| Renal and related cancers | 2021-2025 | 640 | CN 82 | 85.36 |
| Diagnosis and treatment of tuberculosis | 2021-2025 | 246 | CN 24 | 82.92 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 661 | CN 127 | 80.46 |
| Cancer-related Molecular Pathways | 2021-2025 | 545 | CN 102 | 79.77 |
| Biomedical and Engineering Education | 2021-2025 | 222 | CN 11 | 79.15 |
| Traditional Chinese Medicine Studies | 2021-2025 | 288 | CN 211 | 75.09 |
| Nutrition, Genetics, and Disease | 2021-2025 | 792 | CN 80 | 70.51 |
| Biomedical Ethics and Regulation | 2021-2025 | 857 | CN 32 | 56.82 |
| Transgenic Plants and Applications | 2021-2025 | 978 | CN 122 | 50.38 |
| Glutathione Transferases and Polymorphisms | 2021-2025 | 404 | CN 89 | 43.76 |
